This represents Nuwellis’ first pediatric program in the state of Michigan and further expands the Company’s growing presence in pediatric critical care into a significant healthcare market.

The new system installations support the development of clinical protocols and workflows designed to integrate Aquadex therapy into the hospital’s pediatric care program, creating a foundation for future consumable utilization and long-term growth. As Nuwellis continues to prioritize expansion within pediatric and critical care settings, where clinicians are increasingly adopting Aquadex therapy to provide controlled, predictable fluid removal for patients suffering from fluid overload, pediatric programs represent a strategic growth opportunity to broaden access to the therapy and further strengthen the Company’s leadership position in the category.